Copyright (c) 2025 Dr. Jagadeesan M
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
An Interesting Case of Ascites – Budd Chiari Syndrome
Corresponding Author(s) : Dr. Jagadeesan M
International Journal of Allied Medical Sciences and Clinical Research,
Vol. 5 No. 3 (2017): 2017 Volume 5- Issue -3
Abstract
Budd-chiari syndrome is defined as the obstruction of hepatic veins or terminal inferior vena cava (IVC) [1-3].It is a rare disease and can be life-threatening. BCS can be classified as primary when BCS arises from a venous anomaly or as secondary, when an initial lesion is outside the veins. The incidence may be higher in Asian than western population with a slight female preponderance. Hereditary thrombophilia is a condition in which many inherited conditions leading to an increased tendency to develop venous thromboembolism (VTE). Those conditions are very rare. As such BCS is not common in these conditions [3]. In this case report we present a case of Budd- Chiari syndrome with more than one such risk factors
Keywords
-
de Franchis R. Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53, 2010, 762-8.
[2]. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: A review by an expert panel. J Hepatol 38, 2003, 364-71.
Karthick R et al / Int. J. of Allied Med. Sci. and Clin. Research Vol-5(3) 2017 [767-770]
770
[3]. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 49, 2009, 1729-64.
[4]. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al.Etiology, management, and outcome of the Budd-Chiarisyndrome. Ann Intern Med 151, 2009, 167-75.
[5]. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: Consensus and controversies. Hepatology 38, 2003, 793-803.
[6]. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases. Blood 111, 2008, 4922-9.
[7]. Mancuso A. Budd-Chiari syndrome management: lights and shadows. World J Hepatol 3, 2011, 262–264 How to
References
[2]. Janssen HL, Garcia-Pagan JC, Elias E, et al. Budd-Chiari syndrome: A review by an expert panel. J Hepatol 38, 2003, 364-71.
Karthick R et al / Int. J. of Allied Med. Sci. and Clin. Research Vol-5(3) 2017 [767-770]
770
[3]. DeLeve LD, Valla DC, Garcia-Tsao G. Vascular disorders of the liver. Hepatology 49, 2009, 1729-64.
[4]. Darwish Murad S, Plessier A, Hernandez-Guerra M, et al.Etiology, management, and outcome of the Budd-Chiarisyndrome. Ann Intern Med 151, 2009, 167-75.
[5]. Valla DC. The diagnosis and management of the Budd-Chiari syndrome: Consensus and controversies. Hepatology 38, 2003, 793-803.
[6]. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases. Blood 111, 2008, 4922-9.
[7]. Mancuso A. Budd-Chiari syndrome management: lights and shadows. World J Hepatol 3, 2011, 262–264 How to